Table 2.
Patient characteristics.
| Patient characteristics | Negative samples | HIV-1/M ART naive | HIV-1/M ART experienced | HIV-1/O | HIV-2 | PHI |
|---|---|---|---|---|---|---|
| Number | 200 | 100 | 125a | 10 | 15b | 50 |
| Mean Age (±SD) | 28.3 (12.3) | 36.1 (11.9) | 40.5 (11.3) | 42.4 (7.2) | 52.0 (12.8) | ND |
| Sex Ratio (M/F) | 1.0 | 1.7 | 1.3 | 0.1 | 0.4 | 49.0 |
| Mean pVL (log10 cp/mL) (±SD)c | NA | 4.8 (1.06) | 3.7d (0.80) | <1.8 | 3.2e (0.57) | 5.65 (1.17) |
| Min pVL (log10 cp/mL)c | NA | 2.8 | 1.6 | <1.8 | 2.4 | 2.0 |
| Max pVL (log10 cp/mL)c | NA | 6.5 | 6.7 | <1.8 | 3.9 | 7.0 |
| Mean treatment duration (month) (±SD) | NA | NA | 82.7f (66.97) | 72.2 (48.02) | 113.5 (85.98) | NA |
| Mean duration of undetectability (month) (±SD) | NA | NA | 28.2g (29.52) | ND | ND | NA |
| CDC stage | ||||||
| A1 | NA | 11 (11%) | 10 (80%) | ND | 0 (0%) | 50 (100%) |
| A2 | NA | 36 (36%) | 35 (28%) | ND | 5 (33.3%) | 0 (0%) |
| A3 | NA | 19 (19%) | 17 (13.6%) | ND | 0 (0%) | 0 (0%) |
| B1 | NA | 0 (0%) | 2 (1.6%) | ND | 0 (0%) | 0 (0%) |
| B2 | NA | 8 (8%) | 8 (6.4%) | ND | 2 (13.3%) | 0 (0%) |
| B3 | NA | 3 (3%) | 8 (6.4% | ND | 0 (0%) | 0 (0%) |
| C1 | NA | 0 (0%) | 1 (0.8%) | ND | 0 (0%) | 0 (0%) |
| C2 | NA | 2 (2%) | 6 (4.8%) | ND | 0 (0%) | 0 (0%) |
| C3 | NA | 21 (21%) | 30 (24%) | ND | 4 (26.7%) | 0 (0%) |
| ND | NA | 0 (0%) | 8 (6.4%) | ND | 4 (26.7%) | 0 (0%) |
| Total | 200 | 100 | 125 | 10 | 15 | 50 |
| Risk factor | ||||||
| Heterosexual | ND | 56 (56%) | 75 (60%) | 10 (100%) | 14 (93.3%) | ND |
| MSM⁎ | ND | 36 (36%) | 35 (28%) | 0 (0%) | 0 (0%) | ND |
| IDU⁎⁎ | ND | 2 (2%) | 9 (7.2%) | 0 (0%) | 1 (6.7%) | ND |
| MTC⁎⁎⁎ | ND | 0 (0%) | 2 (1.6%) | 0 (0%) | 0 (0%) | ND |
| ND | ND | 6 (6%) | 4 (3.2%) | 0 (0%) | 0 (0%) | ND |
| Total | 200 | 100 | 125 | 10 | 15 | 50 |
ND: not determined; NA: not applicable.
a
pVL < 1.6 log10 cp/mL (n = 55).
b
two patients were co-infected with HIV-1/M.
c
Monitoring pVL: for HIV-1/M, RealTime HIV-1 Abbott Molecular (Rungis, France); for HIV-1/O, group O specific RNA quantification (National Reference Centre on HIV, Rouen, France) [52]; for HIV-2, type 2 specific RNA quantification (National Reference Centre on HIV, Paris, France) [53].
d
pV L > 1.6 log10 cp/mL (n = 70).
e
pVL > 1.7 log10 cp/mL (n = 4).
f
Data available for 108 patients.
g
Mean calculated from follow-up of 38 patients.
⁎
Men who have sex with men.
⁎⁎
Intravenous drug user.
⁎⁎⁎
Mother-to-child infection.